Evidence map›Paper›PMID 31198944›Full record

ArticleThe Journal of infectious diseases2019

Single-Dose Mucosal Immunotherapy With Chimpanzee Adenovirus-Based Vaccine Accelerates Tuberculosis Disease Control and Limits Its Rebound After Antibiotic Cessation.

Sam Afkhami, Rocky Lai, Michael R D'agostino, Maryam Vaseghi-Shanjani, Anna Zganiacz, Yushi Yao, Mangalakumari Jeyanathan, Zhou Xing

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of infectious diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Sam AfkhamiMcMaster Immunology Research Center, McMaster University, Hamilton, Ontario, Canada.
Rocky LaiMcMaster Immunology Research Center, McMaster University, Hamilton, Ontario, Canada.
Michael R D'agostinoMcMaster Immunology Research Center, McMaster University, Hamilton, Ontario, Canada.
Maryam Vaseghi-ShanjaniMcMaster Immunology Research Center, McMaster University, Hamilton, Ontario, Canada.
Anna ZganiaczMcMaster Immunology Research Center, McMaster University, Hamilton, Ontario, Canada.
Yushi YaoMcMaster Immunology Research Center, McMaster University, Hamilton, Ontario, Canada.
Mangalakumari JeyanathanMcMaster Immunology Research Center, McMaster University, Hamilton, Ontario, Canada.
Zhou XingMcMaster Immunology Research Center, McMaster University, Hamilton, Ontario, Canada.
McMaster University · CA

Funding

CIHR
6 · The paper itself

Abstract

backgroundThe development of strategies to accelerate disease resolution and shorten antibiotic therapy is imperative in curbing the global tuberculosis epidemic. Therapeutic application of novel vaccines adjunct to antibiotics represents such a strategy.

methodsBy using a murine model of pulmonary tuberculosis (TB), we have investigated whether a single respiratory mucosal therapeutic delivery of a novel chimpanzee adenovirus-vectored vaccine expressing Ag85A (AdCh68Ag85A) accelerates TB disease control in conjunction with antibiotics and restricts pulmonary disease rebound after premature (nonsterilizing) antibiotic cessation.

resultsWe find that immunotherapy via the respiratory mucosal, but not parenteral, route significantly accelerates pulmonary mycobacterial clearance, limits lung pathology, and restricts disease rebound after premature antibiotic cessation. We further show that vaccine-activated antigen-specific T cells, particularly CD8 T cells, in the lung play an important role in immunotherapeutic effects.

conclusionsOur results indicate that a single-dose respiratory mucosal immunotherapy with AdCh68Ag85A adjunct to antibiotic therapy has the potential to significantly accelerate disease control and shorten the duration of conventional treatment. Our study provides the proof of principle to support therapeutic applications of viral-vectored vaccines via the respiratory route.

Indexed as

AcyltransferasesAdenoviridaeAdministration, IntranasalAnimalsAntigens, BacterialAntitubercular AgentsCombined Modality TherapyDisease Models, AnimalFemaleGenetic VectorsHumansImmunization ScheduleInjections, IntramuscularMiceMycobacterium tuberculosisNasal MucosaAcyltransferasesantigen 85A, Mycobacterium tuberculosisAntigens, BacterialAntitubercular AgentsTuberculosis VaccinesVaccines, Syntheticantibioticsimmunotherapyrespiratory mucosal immunizationtuberculosisviral-vectored vaccines

Identifiers

PMID31198944
PMCPMC6743851
OpenAlexW2952624599

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.